Genzyme Corp (GENZ)
$50.69
-0.38 (-0.74%)
| CAPS Rating |
|
|---|---|
| Open | $51.62 |
| Previous Close | $51.07 |
| Daily Range | $50.69 - $51.82 |
| 52-Week Range | $47.09 - $73.75 |
| Market Cap | $13.45B |
| P/E Ratio | 27.91 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 2,763,256 |
| Average Daily Volume | 4,030,000 |
GENZ
VS S&P 500 (SPY)
How do you think GENZ will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
GENZ Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
GENZ News and Commentary
- Dream Stocks for Biotech Investors – The Motley Fool
- Still Enjoying Those Acquisitions, Pfizer? – The Motley Fool
- UPDATE 1-Genzyme CEO sells 200,000 of company's shares – Reuters
- Wall Street's 10 Favorite Stocks Right Now – The Motley Fool
- Now's a Great Time to Invest -- So Don't Blow It Like This – The Motley Fool
- This Stock Is a Train Wreck – The Motley Fool
- Drug Lowers Cholesterol; Stock Follows – The Motley Fool
- UPDATE 1-Genzyme to stop development of phosphate binder – Reuters
- Genzyme Ends Effort To Develop Stronger Version of Renvela – SmartMoney
- UPDATE: Icahn Reports New Stakes In Genzyme, Forest Labs – SmartMoney
- Icahn Reports New Stakes In Genzyme, Forest Labs At Sept 30 – SmartMoney
- UPDATE: FDA Finds More Deficiencies At Genzyme Plant – SmartMoney
- The S&P 500's Biggest Movers – The Motley Fool
- UPDATE 1-Genzyme says FDA declines to approve Pompe disease drug – Reuters
- FDA Gives Genzyme List Of Fixes Needed Before Drug Approval – SmartMoney
- 2nd UPDATE: Foreign Particles Found In Genzyme Medicines – SmartMoney
- UPDATE: Foreign Particles Found In Some Genzyme Medicines – SmartMoney
- Fox Business on Genzyme Corp. – Ockham-RazorWire
- Fox Business on Genzyme Corp. – Ockham-RazorWire
- UPDATE 1-U.S. FDA: Some Genzyme drugs contaminated – Reuters
RSS Headlines
Fool UK
